Global Age-related Macular Degeneration Market Size to Exceed USD 23.46 Million by 2035 | CAGR of 6.48%

Global Age-related Macular Degeneration Market Size to Exceed USD 23.46 Million by 2035

According to a Research Report Published by Decisions Advisors & Consulting, The Global Age-related Macular Degeneration Market Size is expected to Grow from USD 11.76 Million in 2024 to USD 23.46 Million by 2035, at a CAGR of 6.48% during the forecast period 2025-2035.  

Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the "Global Age-related Macular Degeneration Market Size, Share, and COVID-19 Impact Analysis, By Product (Eylea, Lucentis, Beovu, Vabysmo, Syfovre, Avastin, and Others), By Disease Type (Wet AMD, and Dry AMD), By Age Group (50–64 years, 65–74 years, and 75 and above), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035."

Get Detailed Report Description Here: https://www.decisionsadvisors.com/reports/age-related-macular-degeneration-market                   

The global market for age-related macular degeneration (AMD), a progressive retinal disease that damages the macula and causes central vision loss, refers to the development, commercialisation, and distribution of treatments, diagnostics, and supportive technologies aimed at preventing, slowing, or treating AMD. The disease specifically damages the macula, the core part of the retina that gives sharp, central vision. The AMD market includes medications used to treat AMD, a degenerative disease that damages the macula, the centre of the retina, and results in central vision loss. It is anticipated that the introduction of new products, a strong development pipeline, and a rise in the prevalence of AMD would be significant market drivers. Advanced pharmaceutical research, enhanced healthcare infrastructure, and strong regional government are backing the expansion. However, Growth in the market is constrained by high costs, stringent regulations, and several difficulties. 

The Eylea segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.       

Based on the product, the age-related macular degeneration market is segmented into Eylea, Lucentis, Beovu, Vabysmo, Syfovre, Avastin, and others. Among these, the Eylea segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. This is due to its shown efficacy, longer dose intervals, and high physician approval, and it has resulted in prolonged and ongoing use, with more annual prescriptions than previous treatments and better patient outcomes.

The wet AMD dominated the market in 2024 and is anticipated to grow at a substantial CAGR over the forecast period.       

Based on the disease type, the age-related macular degeneration market is divided into wet AMD and dry AMD. Among these, the wet AMD dominated the market in 2024 and is anticipated to grow at a substantial CAGR over the forecast period. The market for treatments for age-related macular degeneration has grown as a result of the ageing population and breakthroughs in AMD treatment technology.

The 65–74 segment accounted for the highest market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.     

Based on the age group, the age-related macular degeneration market is segmented into 50–64 years, 65–74 years, and 75 and above. Among these, the 65–74 segment accounted for the highest market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The 65-74 age group is more likely to use services such as online instructional content, home delivery of AREDS2 supplements, and eye injection reminders, which all increase income for the segment.

Asia Pacific is expected to hold the majority share of the global age-related macular degeneration market during the forecast period.       

Asia Pacific is expected to hold the majority share of the global age-related macular degeneration market during the forecast period. The main forces behind this region's expansion are the quick advancements in the healthcare sector in countries like China, Japan, India, and a few others. The public and private sectors' growing interest in research and development linked to the treatment of age-related macular degeneration has also contributed to the growth of the market for such treatments.

North America is anticipated to grow at the fastest pace in the global age-related macular degeneration market during the forecast period. The main factor propelling this region's growth is the expanding technological developments in the healthcare industry. Additionally, the need for AMD treatment has increased due to the rising prevalence of age-related macular degeneration (AMD) problems in countries like the United States and Canada, driving market expansion.

Major vendors in the global age-related macular degeneration market are Amgen, Apellis Pharmaceuticals, Bayer, Biocon Biologics, Celltrion, F. Hoffmann-La Roche, Formycon, Novartis, Pfizer, Regeneron Pharmaceuticals, Sandoz Group, STADA Arzneimittel, Xbrane Biopharma, and Others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development   

• In December 2025, Regenerative Patch Technologies (RPT) started the Phase IIb clinical study of an allogeneic bioengineered retinal pigment epithelial (RPE) cell implant, addressing the first two patients who have sophisticated dry age-related macular degeneration (AMD). This is an important step in verifying the durability, safety, and efficacy signals found in previous trials.

Market Segment  

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the age-related macular degeneration market based on the below-mentioned segments:  

Global Age-related Macular Degeneration Market, By Product

• Eylea
• Lucentis
• Beovu
• Vabysmo
• Syfovre
• Avastin
• Others

Global Age-related Macular Degeneration Market, By Disease Type

• Wet AMD
• Dry AMD

Global Age-related Macular Degeneration Market, By Age Group

• 50–64 years
• 65–74 years
• 75 and above

Global Age-related Macular Degeneration Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa